Home/Pipeline/Rheumatoid Arthritis Therapy Guidance Test

Rheumatoid Arthritis Therapy Guidance Test

Rheumatoid Arthritis

Pre-clinical/Clinical StudyActive

Key Facts

Indication

Rheumatoid Arthritis

Phase

Pre-clinical/Clinical Study

Status

Active

Company

Aqtual

About Aqtual

Aqtual is an early-stage diagnostics company developing a novel platform to extract clinically actionable insights from circulating chromatin and cell-free DNA. Its proprietary biochemistry and data science approach enables the creation of a catalog of disease-specific signatures, with an initial focus on guiding therapy management for rheumatoid arthritis patients. The company is conducting a prospective clinical study to validate its test in a real-world setting, positioning it to address significant unmet needs in precision medicine for chronic inflammatory diseases and oncology.

View full company profile

Therapeutic Areas

Inflammatory conditions Oncology Immunology Cardiovascular diseases Metabolic diseases Neurological conditions

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Monoclonal Antibody Biosimilar (Anti‑TNF)	USV Biologics Division	Phase 1	Active
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active